# Apollon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apollon

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.apollon.bio
- Total disclosed funding: $3.6M
- Latest round: Series A (Sep 23, 2026)
- Investors on record: 9

## About

Based in Seoul, South Korea, and founded in 2021, Apollon Inc. operates as a provider of needleless glucose monitoring devices. As of 2023, the company is headed by its CEO Aram Hong. In September 2026, Apollon Inc. raised KRW 5 billion in series A funding led by SBI Investment, with participation from Naver, Daewoong Pharmaceutical, Korea Credit Guarantee Fund, and Mirae Holdings.

The company develops and manufactures needleless continuous glucose monitoring (CGM) equipment using in vivo Raman glucose peaks that measure blood sugar levels in patients. The firm device is of smartwatch size without any needle and sensor applicator.

The company plans to use the September 2026 funding to conduct a clinical feasibility study and engage with the US Food and Drug Administration.

## Funding rounds

- Series A, Sep 23, 2026, $3.6M — SBI Investment, Naver, Korea Credit Guarantee Fund, Mirae Holdings, Daewoong Pharmaceutical
- Seed, Sep 1, 2023 — Korea Tech Incubator for Startup, Ulsan Creative Economy Innovation Center
- Seed, Jan 1, 2023 — Be High Investment, Ulsan Creative Economy Innovation Center, The Ventures

## Investors

- Be High Investment (https://capitalatlas.ai/funds/be-high-investment) — Seed
- Ulsan Creative Economy Innovation Center (https://capitalatlas.ai/funds/ulsan-creative-economy-innovation-center) — Seed
- The Ventures (https://capitalatlas.ai/funds/the-ventures) — Seed
- Korea Tech Incubator for Startup — Seed
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- Naver — Series A
- Korea Credit Guarantee Fund — Series A
- Mirae Holdings (https://capitalatlas.ai/funds/mirae-holdings) — Series A
- Daewoong Pharmaceutical — Series A